Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal

Reuters2026/08/17 11:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fulcrum Therapeutics agreed to an all-stock merger with Slate Medicines, creating a migraine-focused company to be renamed Slate Medicines.
Combined shares expected to trade on Nasdaq under ticker SLTE once the deal closes.
Slate secured USD 245 million in an oversubscribed private placement set to close alongside the merger, funding operations into 2029.
Slate’s lead asset SLTE-1009 targets PACAP/VIP for migraine prevention; Phase 1 data expected mid-2027.
Fulcrum plans a pre-close cash dividend tied to net cash above USD 20.3 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608170700PRIMZONEFULLFEED9811004) on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal

You may also like

Crypto prices